Navigation Links
Experimental obesity drug avoids brain effects that troubled predecessors
Date:7/12/2010

Stockholm, Sweden: A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.

The first generation of anti-obesity drugs that targeted the cannabinoid receptor CB1 such as rimonabant - showed great promise as a therapy for obesity and related diseases such as diabetes. However, they were troubled by risk of psychiatric side effects. Rimonabant was withdrawn from the European market following a recommendation by the European Medicines Agency in late 2008, while further development of other similar products was halted.

However, in a study presented today (Monday) at the International Congress on Obesity in Stockholm, Sweden, Danish researchers demonstrated in rodents that a new first-in-class, second-generation CB1 receptor blocker induced the same degree of weight loss as rimonabant while not exposing the brain to significant levels of the drug. The drug was designed to act selectively in peripheral tissues and organs, in contrast with the first generation of CB1 receptor blockers, which also significantly affected the brain.

"These findings, together with what we have seen in our first human study regarding the safety and tolerability, make this drug candidate a promising therapy for obesity and diabetes. The lack of significant exposure in the brain seen in our preclinical experiments provides optimism that blockade of the CB1 receptor may still be an effective and safe approach to treat obesity and related diseases," said Christian E. Elling, Vice President at 7TM Pharma A/S in Hoersholm, Denmark, who presented the findings at the conference. "This is, to our knowledge, the first peripheral CB1 drug candidate being tested in humans and these results indicate its development as a potential new treatment should be advanced."

In the rodent studies, the researchers conducted an extensive panel of studies with mice and rats to assess the weight-loss and anti-diabetic potential of the as-yet unnamed drug, TM38837, and to demonstrate the lack of exposure in the brain.

The researchers treated obese rats and mice with rimonabant, the new drug, or a placebo drug once a day for five weeks and measured their body weight and food intake daily. Animals lost an equal amount of body weight when treated with similar doses of rimonabant and TM38837. At the end of the treatment period, drug treated mice had 22-26% lower body weights than placebo treated mice while drug treated rats had 14% lower body weights than placebo treated rats.

Other animal studies provided substantial evidence that the drug has a markedly lower propensity than rimonabant to cross the blood-brain barrier. These studies included brain tissue examination, behavioural tests and other studies to demonstrate where in the body the drug was distributed.

For their human study of the drug, the researchers reported that in a phase 1 clinical trial of 48 healthy normal-weight adults, the drug was well tolerated even at the highest dose, with seven of the volunteers experiencing brief, mild drug-related side effects such as abdominal discomfort, nausea and diarrhoea.

On the basis of these results, development of the drug is continuing. The researchers expect to report the results of further animal and human studies this autumn.


'/>"/>

Contact: Emma Ross
rosswrite@mac.com
International Association for the Study of Obesity
Source:Eurekalert

Related medicine news :

1. Experimental nonsteroidal treatment of asthma shows promise
2. Experimental targeted therapy shows early promise against medulloblastomas
3. Experimental Vaccine Shields Monkeys Against Ebola
4. Experimental Drug Offers Hope for Cystic Fibrosis Patients
5. Childhood Obesity Boosts Risk of GERD
6. Inactivity no contributor to childhood obesity epidemic
7. New Book Helps Combat America's Child Obesity Epidemic
8. Zone Diet Creator Dr. Sears Discusses Obesity Causes and Solutions on Mel Robbins Radio Show
9. Obesity in America: World-Renowned Health Educator Offers Solutions to Obesity Epidemic
10. The Quantum Scale Helps in the Fight Against Childhood Obesity
11. Obesity Rates Jump in 28 States, Report Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , ... January 20, 2017 , ... “The Land of ... attention to the issue of world hunger, and shares the simple and achievable answer. ... devoted husband and member of the Fairview Missionary Church in Angola, Indiana where he ...
(Date:1/19/2017)... ... ... Today, the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 clinicians ... Clinicians who participate in APMs are paid for the quality of care they give ... build a system that delivers better care and one in which clinicians work together ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
(Date:1/19/2017)... LINCOLN, R.I. (PRWEB) , ... January 19, 2017 , ... With the cold weather here, ... sidewalks. , Snow blowers are efficient when clearing large amounts of snow, but they can ... tips from the U.S. Consumer Product Safety Commission for the proper use of snow blowers:, ...
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots , the ... around the world, announces the launch of its newly redesigned website. The sleek ... research breakthroughs and trending news, vital information on upcoming virtual events and webinars, ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017 Entscheidung fällt ... Die internationale humanitäre Stadt soll um knapp ... Seine Hoheit Scheich Muhammad bin ... Herrscher von Dubai , hat den ... (International Humanitarian City IHC) zu verdreifachen, um den Betrieb ...
(Date:1/19/2017)... 19, 2017 The Global Therapy Partnering Terms ... to partnering deals and agreements entered into by the ... deals - Top deals by value - Deals listed ... type The report provides understanding and access to ... world,s leading healthcare companies. The report provides an ...
(Date:1/19/2017)... 19, 2017 Many patients don,t realize that ... when a pharmacy just a few blocks away charges ... this problem Medicationdiscountcard.com has created a price ... how much their medication will cost at most nearby ... Medicationdiscountcard.com takes all of ...
Breaking Medicine Technology: